AU7310496A - Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy - Google Patents

Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy

Info

Publication number
AU7310496A
AU7310496A AU73104/96A AU7310496A AU7310496A AU 7310496 A AU7310496 A AU 7310496A AU 73104/96 A AU73104/96 A AU 73104/96A AU 7310496 A AU7310496 A AU 7310496A AU 7310496 A AU7310496 A AU 7310496A
Authority
AU
Australia
Prior art keywords
outcome
predicting
methods
hbv infection
cytokine therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73104/96A
Other languages
English (en)
Inventor
Adrian Vivian Sinton Hill
Dimitris Mantafounis
Howard Christopher Thomas
Mark Richard Thursz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College of Science Technology and Medicine
Original Assignee
Imperial College of Science Technology and Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9520993.8A external-priority patent/GB9520993D0/en
Priority claimed from GBGB9619233.1A external-priority patent/GB9619233D0/en
Application filed by Imperial College of Science Technology and Medicine filed Critical Imperial College of Science Technology and Medicine
Publication of AU7310496A publication Critical patent/AU7310496A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU73104/96A 1995-10-13 1996-10-14 Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy Abandoned AU7310496A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9520993.8A GB9520993D0 (en) 1995-10-13 1995-10-13 Predictive test
GB9520993 1995-10-13
GB9619233 1996-09-13
GBGB9619233.1A GB9619233D0 (en) 1996-09-13 1996-09-13 Method for predicting development of persistent HBV infection
PCT/GB1996/002519 WO1997013875A1 (fr) 1995-10-13 1996-10-14 Procedes pour prevoir l'evolution d'une infection persistante par hbv et le resultat d'une therapie aux cytokines

Publications (1)

Publication Number Publication Date
AU7310496A true AU7310496A (en) 1997-04-30

Family

ID=26307946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73104/96A Abandoned AU7310496A (en) 1995-10-13 1996-10-14 Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy

Country Status (3)

Country Link
EP (1) EP0862652A1 (fr)
AU (1) AU7310496A (fr)
WO (1) WO1997013875A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9817266D0 (en) * 1998-08-07 1998-10-07 Imperial College Method
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
FI20070795A0 (fi) 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
WO2015091306A1 (fr) * 2013-12-17 2015-06-25 F. Hoffmann-La Roche Ag Biomarqueurs pour la réponse au traitement du virus de l'hépatite b
JP2018500903A (ja) * 2014-12-18 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖ治療反応に関するバイオマーカー

Also Published As

Publication number Publication date
WO1997013875A1 (fr) 1997-04-17
EP0862652A1 (fr) 1998-09-09

Similar Documents

Publication Publication Date Title
AU5268696A (en) Novel compounds and methods for therapy
AU5750796A (en) System for the treatment of insomnia
AU6391394A (en) Medical devices and methods of manufacture
AU5259296A (en) Flavones and coumarins as agents for the treatment of athero sclerosis
AU7443496A (en) Treatment of migraine
AUPN271295A0 (en) Method of treatment
AU6226894A (en) Implantable therapy systems and methods
AU5147996A (en) Gene therapy for transplantation and inflammatory or thrombo tic conditions
AU6104896A (en) Therapeutic microdevices and methods of making and using sam e
AU2453597A (en) Metal casket and method of making the same
AU7310496A (en) Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
AUPN104895A0 (en) Methods of and preparations for the treatment of ailments and disorders
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
AU7482696A (en) Methods for administration of il-12
AU4272996A (en) Means for treatment of particle mass
AU2028297A (en) Method for predicting the outcome of hepatitis b infection
AU4604697A (en) Compositions and methods for the treatment of human cytomegalovirus infection
AU2992295A (en) Therapeutic method and compounds of use therein
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
AU4319393A (en) Use of indolocarbazols in aids treatment
AU6388396A (en) Electromagnetic therapeutic treatment device and methods of using same
AU6171196A (en) Therapeutic uses of ta99
AU4552496A (en) Screeding devices and methods of use
AU6623096A (en) Methods of predicting the outcome of infection
AU4223289A (en) Treatment of metal slabs